双膦酸盐和地舒单抗在早期乳腺癌骨健康管理中的研究进展  

Research progress of bisphosphonate and denosumab in bone health management of early breast cancer

作　　者：陈舒淇 车名花 张万丽 周文斌[3] 何畏[1] Chen Shuqi;Che Minghua;Zhang Wanli;Zhou Wenbin;He Wei(Department of Endocrinology,First Affiliated Hospital,Nanjing Medical University,Nanjing 210029,China;Department of Endocrinology,Yixing Hospital of Traditional Chinese Medicine,Yixing 214299,China;Department of Breast Surgery,First Affiliated Hospital,Nanjing Medical University,Nanjing 210029,China)

机构地区：[1]南京医科大学第一附属医院内分泌科,210029 [2]宜兴市中医医院内分泌科,214299 [3]南京医科大学第一附属医院乳腺外科,210029

出　　处：《中华内分泌代谢杂志》2025年第1期65-69,共5页Chinese Journal of Endocrinology and Metabolism

摘　　要：早期乳腺癌患者常会发生继发性骨质疏松症, 出现腰背疼痛、骨关节症状和骨质疏松性骨折, 而双膦酸盐和地舒单抗可通过减少骨量流失降低骨折发生率, 但在疗效、疗程及不良反应上各有特点, 患者选择药物需权衡利弊;近来还有关于其降低骨转移发生率的研究。本文就这两种药物在早期乳腺癌骨健康管理中的最新应用进展作出综述。Secondary osteoporosis is common in patients with early breast cancer,manifesting as low back pain,bone and joint symptoms,and osteoporotic fractures.Bisphosphonate and denosumab can reduce the incidence of fractures by minimizing bone loss,though they differ in efficacy,treatment course,and side effects.Patients should consider the pros and cons when selecting a drug.Recent studies also focus on decreasing the incidence of bone metastases.This article reviews recent advancements in the use of these two drugs for managing bone health in early breast cancer.

关 键 词：双膦酸盐 地舒单抗 早期乳腺癌 骨质流失 辅助治疗 

分 类 号：R737.9[医药卫生—肿瘤]